154 related articles for article (PubMed ID: 10233911)
1. Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression.
Holzer GW; Remp G; Antoine G; Pfleiderer M; Enzersberger OM; Emsenhuber W; Hämmerle T; Gruber F; Urban C; Falkner FG; Dorner F
J Virol; 1999 Jun; 73(6):4536-42. PubMed ID: 10233911
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
[TBL] [Abstract][Full Text] [Related]
3. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
4. Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.
Tsetsarkin KA; Maximova OA; Liu G; Kenney H; Teterina NL; Pletnev AG
mBio; 2019 Apr; 10(2):. PubMed ID: 31015334
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
Fleeton MN; Sheahan BJ; Gould EA; Atkins GJ; Liljestr M P
J Gen Virol; 1999 May; 80 ( Pt 5)():1189-1198. PubMed ID: 10355766
[TBL] [Abstract][Full Text] [Related]
6. A study of systems for delivering antigens and plasmid DNA for intranasal immunization against tick-borne encephalitis virus.
Goncharova EP; Ryzhikov AB; Bulychev LE; Sizov AA; Lebedev LR; Poryvaev VD; Karpenko LI; Il'ichev AA
Wien Klin Wochenschr; 2002 Jul; 114(13-14):630-5. PubMed ID: 12422616
[TBL] [Abstract][Full Text] [Related]
7. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.
Schmaljohn C; Vanderzanden L; Bray M; Custer D; Meyer B; Li D; Rossi C; Fuller D; Fuller J; Haynes J; Huggins J
J Virol; 1997 Dec; 71(12):9563-9. PubMed ID: 9371620
[TBL] [Abstract][Full Text] [Related]
8. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
[TBL] [Abstract][Full Text] [Related]
9. Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis.
Dmitriev IP; Khromykh AA; Ignatyev GM; Gainullina MN; Ageenko VA; Dryga SA; Vorobyeva MS; Sandakhchiev LS
J Biotechnol; 1996 Jan; 44(1-3):97-103. PubMed ID: 8717392
[TBL] [Abstract][Full Text] [Related]
10. A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection.
Kubinski M; Beicht J; Zdora I; Biermann J; Puff C; Gerlach T; Tscherne A; Baumgärtner W; Osterhaus ADME; Sutter G; Prajeeth CK; Rimmelzwaan GF
Front Immunol; 2023; 14():1182963. PubMed ID: 37153588
[TBL] [Abstract][Full Text] [Related]
11. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
Taylor J; Paoletti E
Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
[TBL] [Abstract][Full Text] [Related]
12. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
Moss B
Dev Biol Stand; 1994; 82():55-63. PubMed ID: 7958483
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
Domnich A; Panatto D; Arbuzova EK; Signori A; Avio U; Gasparini R; Amicizia D
Hum Vaccin Immunother; 2014; 10(10):2819-33. PubMed ID: 25483679
[TBL] [Abstract][Full Text] [Related]
14. Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins.
Himly M; Pfleiderer M; Holzer G; Fischer U; Hannak E; Falkner FG; Dorner F
Protein Expr Purif; 1998 Dec; 14(3):317-26. PubMed ID: 9882565
[TBL] [Abstract][Full Text] [Related]
15. Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins.
Wyatt LS; Xiao W; Americo JL; Earl PL; Moss B
mBio; 2017 Jun; 8(3):. PubMed ID: 28588133
[TBL] [Abstract][Full Text] [Related]
16. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
17. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
Viner KM; Girgis N; Kwak H; Isaacs SN
Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
[TBL] [Abstract][Full Text] [Related]
18. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
[TBL] [Abstract][Full Text] [Related]
19. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV.
Phillpotts RJ; Lescott TL; Jacobs SC
Acta Virol; 2000 Oct; 44(5):233-9. PubMed ID: 11252667
[TBL] [Abstract][Full Text] [Related]
20. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection.
Mason PW; Pincus S; Fournier MJ; Mason TL; Shope RE; Paoletti E
Virology; 1991 Jan; 180(1):294-305. PubMed ID: 1845826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
